You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carcinoma of the Bladder

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)

Not yet recruiting
  • Neuroendocrine Carcinoma of the Bladder
  • Bladder Cancer
  • (no location specified)
Oct 14, 2023

Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Urothelial Carcinoma Bladder
  • PD-1 Inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022

Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in United States (UGN-102)

Active, not recruiting
  • Bladder Cancer
  • +2 more
  • Homewood, Alabama
  • +4 more
Dec 15, 2022

Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder Trial in Washington, Baltimore

Recruiting
  • Small Cell Neuroendocrine Carcinoma of Bladder
  • +2 more
  • Washington, District of Columbia
  • +1 more
Jun 27, 2022

Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder Trial in United States (UGN-301, UGN-201)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • +5 more
  • Little Rock, Arkansas
  • +7 more
Dec 19, 2022

High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder Trial in Washington, Baltimore (Enfortumab

Not yet recruiting
  • High Grade Urothelial Carcinoma
  • +2 more
  • Washington, District of Columbia
  • +1 more
Jan 5, 2023

Biomarkers in Bladder Urothelial Carcinoma

Completed
  • Bladder Cancer
  • Free glycosaminoglycan profiling
  • Gothenburg, Sweden
    Department of Urology, Institute of Clinical Science, Sahlgrensk
Apr 3, 2023

Cisplatin-Ineligible Metastatic Bladder Cancer and The Role of

Not yet recruiting
  • Bladder Cancer
  • +3 more
  • Geriatric-8 Survey
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 14, 2023

Preferences for Japanese Muscle-invasive Urothelial Carcinoma of

Not yet recruiting
  • Urinary Bladder Neoplasms
    • (no location specified)
    Feb 14, 2023

    Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis Trial (Bacillus Calmette Guerin)

    Not yet recruiting
    • Urothelial Carcinoma Bladder
    • +2 more
    • Bacillus Calmette Guerin
    • (no location specified)
    Jan 18, 2023

    Bladder Bank (a Prospective Banking Study)

    Recruiting
    • Bladder Carcinoma
    • Hematuria
    • Non-Interventional Study
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Oct 25, 2023

    Bladder Cancer, Bladder Cancer Recurrent, Tumor Recurrence Trial (Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus

    Not yet recruiting
    • Bladder Cancer
    • +5 more
    • Bacillus Calmette-Guerin: Strain Russian BCG-I
    • Bacillus Calmette-Guerin: Strain TICE
    • (no location specified)
    Apr 7, 2022

    Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder

    Not yet recruiting
    • Non-muscle-invasive Bladder Cancer
    • +2 more
    • PDD-TURBT with hexaminolevulinate (Hexvix®)
    • Power Led Saphira (TM) from KARL STORZ
    • (no location specified)
    Jul 24, 2023

    Bladder Cancer Trial in Lausanne (Flexible cystoscopy, Urinary catheter)

    Active, not recruiting
    • Bladder Cancer
    • Flexible cystoscopy
    • Urinary catheter
    • Lausanne, VD, Switzerland
      Centre Hospitalier Universitaire Vaudois, CHUV
    Dec 1, 2022

    Avelumab First-Line Maintenance in Canadian People With Advanced

    Not yet recruiting
    • Urinary Bladder Neoplasms
    • +3 more
    • Avelumab first-line maintenance
    • Mississauga, Ontario, Canada
      Bayshore Specialty Rx
    Jan 24, 2023

    Analytical Specificity of Bladder EpiCheck Test in Healthy

    Completed
    • Non Muscle Invasive Bladder Cancer
    • Non-Muscle Invasive Bladder Urothelial Carcinoma
    • Bladder EpiCheck
    • San Antonio, Texas
      Urology San Antonio
    Sep 3, 2023

    Urothelial Carcinoma Trial (Disitamab Vedotin, radiotherapy)

    Not yet recruiting
    • Urothelial Carcinoma
    • Disitamab Vedotin
    • radiotherapy
    • (no location specified)
    Jun 20, 2023

    Can Second Resection for pT1 Bladder Cancer be Avoided After

    Recruiting
    • Bladder Cancer Stage I
    • Avoid second resection after initial complete resection
    • Mansoura, Dakahlia, Egypt
      Urology and nephrology center, Mansoura University
    Aug 2, 2023

    Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab

    Not yet recruiting
    • Localized Muscle Invasive Bladder Urothelial Carcinoma
    • Muscle-Invasive Bladder Carcinoma
    • Sacituzumab govitecan
    • Adaptive Radiotherapy
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
    Apr 18, 2023

    Protocol for Muscle Invasive Urothelial Carcinoma of Urinary

    Recruiting
    • Bladder Cancer
    • terta modal bladder preservation
    • Assiut, Assuit, Egypt
      Assuit university
    Aug 13, 2022

    Neutrophils to Lymphocytes Ratio in Predicting Response to BCG

    Completed
    • Urinary Bladder Cancer
    • +4 more
    • Neutrophil to lymphocyte ratio
    • Cairo, Egypt
      Ain Shams university
    Jul 15, 2023

    High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications Trial

    Recruiting
    • High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
    • +2 more
    • hyperthermic intravesical perfusion
    • Zhengzhou, Henan, China
      BR-PRG
    Sep 15, 2022

    Metastatic Urothelial Carcinoma Trial (Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring)

    Not yet recruiting
    • Metastatic Urothelial Carcinoma
    • Pembrolizumab (200mg)
    • +2 more
    • (no location specified)
    Sep 18, 2023